Encrypted login | home

Program Information

Joint Symposium of AAPM and ASTRO: Normal Tissue Dose-Volume Effects of Head/Neck and Liver/GI SBRT

M Miften
no image available
B Kavanagh

P Mavroidis

V Moiseenko

M Miften1*, B Kavanagh2*, P Mavroidis3*, V Moiseenko4*, (1) University of Colorado School of Medicine, Aurora, CO, (2) University of Colorado Health Science, Aurora, CO, (3) University North Carolina, Chapel Hill, NC, (4) UC San Diego, La Jolla, CA


10:00 AM : Radiation Dose-Volume Effects for Liver SBRT - M Miften, Presenting Author
10:30 AM : Clinical Aspects of SBRT in Abdominal Regions - B Kavanagh, Presenting Author
11:00 AM : Modelling Radiation Dose-Volume Tolerance based on data from Hypofractionated Head and Neck Retreatments - P Mavroidis, Presenting Author
11:30 AM : Volume Effects and Reporting Standards for SBRT - V Moiseenko, Presenting Author

TH-CD-FS1-0 (Thursday, August 3, 2017) 10:00 AM - 12:00 PM Room: Four Seasons 1

Treatment sites such as liver and recurrent head and neck tumors have had limited success with conventional fractionation, but stereotactic body radiation therapy (SBRT) and stereotactic ablative body radiotherapy (SABR) have demonstrated efficacy and low toxicity for these challenging indications. The AAPM SBRT Working Group (WGSBRT) has investigated these outcomes as part of a project called High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC). After a brief overview of treatment efficacy, this session will focus on new normal tissue complication probability (NTCP) results for SBRT/SABR of liver and adjacent gastrointestinal (GI) structures, as well as for critical structures near re-irradiated head and neck (HN) tumors.

Learning Objectives:
1. Efficacy of current SBRT and hypofractionation schedules
2. Normal tissue tolerance for SBRT and hypofractionated treatments
3. Radiobiology and modeling based on published reports

Funding Support, Disclosures, and Conflict of Interest: Dr. Grimm designed and holds intellectual property rights to the DVH Evaluator software tool which is an FDA-cleared product in commercial use.


Contact Email: